
SYN
Healthcare · Biotechnology · $16.2M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · -875.0% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 1, 2022 | After the close | -0.40 | -0.33 | +17.5% |
| Aug 11, 2022 | Before the open | -0.35 | -0.31 | +11.4% |
| May 16, 2022 | Before the open | -0.30 | -0.30 | 0.0% |
| Mar 16, 2022 | After the close | -0.30 | -0.40 | -33.3% |
| Nov 3, 2021 | After the close | -0.25 | -0.20 | +20.0% |
| Aug 5, 2021 | After the close | -0.20 | -0.20 | 0.0% |
| May 5, 2021 | After the close | -0.20 | -1.30 | -550.0% |
| Mar 4, 2021 | After the close | -0.80 | -1.40 | -75.0% |
| Nov 10, 2020 | After the close | -1.70 | -1.40 | +17.6% |
| Aug 6, 2020 | After the close | -1.60 | -1.80 | -12.5% |
| May 5, 2020 | After the close | -0.27 | -0.20 | +25.9% |
| Feb 20, 2020 | After the close | -0.23 | -0.19 | +17.4% |
| Nov 4, 2019 | After the close | -0.23 | -0.30 |
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of…
| -30.4% |
| Aug 8, 2019 | After the close | -0.23 | -0.22 | +4.3% |
| May 8, 2019 | After the close | -0.23 | -0.22 | +4.3% |
| Feb 27, 2019 | After the close | -0.81 | -0.28 | +65.4% |
| Nov 8, 2018 | After the close | -1.32 | -0.91 | +31.1% |
| Aug 8, 2018 | After the close | -1.40 | -1.16 | +17.1% |
| May 8, 2018 | After the close | -1.75 | -0.65 | +62.9% |
| Feb 22, 2018 | Before the open | -1.63 | 0.70 | +142.9% |